Safety and Efficacy of Stereotactic Body Radiotherapy for Stage I Non-Small-Cell Lung Cancer in Routine Clinical Practice: A Patterns-of-Care and Outcome Analysis [1]
A retrospective analysis of SBRT in 13 institutions over a 10 year interval was conducted on outcomes in 582 pts with Stage I NSCLC. At 3 years, freedom from local recurrence was 80% and overall survival was 47%. The biological dose was the most important determinant of outcomes. With higher effective dosing, freedom from local recurrence was 92% and overall survival was 62%.
Source name:
Journal of Thoracic Oncology